Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dr. Reddy's Laboratories Ltd ADR (NY: RDY ) 81.22 +0.38 (+0.47%) Official Closing Price Updated: 7:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 250,264 Open 81.21 Bid (Size) 66.02 (1) Ask (Size) 83.61 (1) Prev. Close 80.84 Today's Range 81.16 - 81.98 52wk Range 63.72 - 81.98 Shares Outstanding 166,301,231 Dividend Yield 1.20% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Dr. Reddy’s Q1FY25 Financial Results Today 9:51 EDT From Dr. Reddy’s Laboratories Ltd. Via Business Wire Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem July 10, 2024 Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 Via MarketBeat Performance YTD +14.67% +14.67% 1 Month +12.76% +12.76% 3 Month +8.95% +8.95% 6 Month +16.80% +16.80% 1 Year +19.55% +19.55% More News Read More Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)? July 01, 2024 Via Chartmill Dr. Reddy's Labs Stock Sees Improved Technical Strength June 28, 2024 Via Investor's Business Daily Dr Reddy's Laboratories: Q3 Earnings Insights January 30, 2024 Via Benzinga Is NYSE:RDY suited for quality investing? September 14, 2023 Via Chartmill Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M June 26, 2024 Via Benzinga Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business June 26, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities June 03, 2024 From Aurigene Pharmaceutical Services Ltd. Via Business Wire India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. June 03, 2024 Via Investor's Business Daily Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America May 28, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Alvotech Via GlobeNewswire RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 May 07, 2024 Via InvestorPlace Dr. Reddy’s Q4 & Full Year FY24 Financial Results May 07, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. May 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK March 19, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand February 22, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Dr. Reddy’s Q3 & 9M FY24 Financial Results January 31, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands January 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index December 14, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) December 06, 2023 From Coya Therapeutics, Inc. Via Business Wire 2 overlooked stocks that crushed earnings but traded lower November 20, 2023 Via MarketBeat Exposures Product Safety Dr. Reddy’s Q2 FY24 Financial Results October 27, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. October 24, 2023 Via Chartmill Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.